Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The equity awards vest over four annual installments, with continued employment required on each vesting date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Praxis Precision Medicines (Nasdaq: PRAX) granted restricted stock units covering 23,219 common shares on November 2, 2026, to new non-executive employees.
The awards went to 59 employees under the 2024 Inducement Plan as employment inducements under Nasdaq Listing Rule 5635(c)(4). They vest in four equal annual installments, subject to continued employment on each vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Restricted stock units covering 23,219 shares create potential dilution as awards vest for 59 new non-executive employees.
Key Figures
- Restricted stock units
- 23,219 shares
- Aggregate awards to new employees
- Recipients
- 59 non-executive employees
- New employees receiving awards
- Vesting schedule
- 4 equal annual installments
- Subject to continued employment on each vesting date
Historical Context
-
Granted restricted stock units to new non-executive employees under the 2024 Inducement Plan.
-
Granted restricted stock units to new non-executive employees under the 2024 Inducement Plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock unit financial
central nervous system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on November 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 23,219 shares of its common stock to fifty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What inducement awards did Praxis Precision Medicines grant in November 2026?
Praxis granted restricted stock units covering 23,219 common shares to 59 new non-executive employees on November 2, 2026. The awards were employment inducements under the 2024 Inducement Plan.
What is the vesting schedule for Praxis Precision Medicines' November 2026 inducement awards?
The restricted stock units vest in four equal annual installments, subject to the employee remaining employed by Praxis on each vesting date.